Bipolar II Disorder

A COMPASS Pathways (NASDAQ: CMPS)-backed clinical trial assessing psilocybin-assisted psychotherapy for bipolar II disorder has provided preliminary data on the treatment’s safety and efficacy, reported Marijuana Moment’s Ben Adlin. Published by the Journal of the American...